Introduction {#Sec1}
============

Lipodystrophies are a group of diseases mainly characterized by a loss or lack of adipose tissue, although in some cases, some areas of lipohypertrophy also appear \[[@CR1]\]. Frequently, lipodystrophic syndromes are associated with metabolic and hepatic disturbances, such as insulin resistance, atherogenic dyslipidaemia, and hepatic steatosis. These complications are usually responsible for serious co-morbidities (diabetes mellitus, cardiovascular diseases, acute pancreatitis, and cirrhosis) and mortality. As fat loss becomes more severe, associated complications will become more severe.

Lipodystrophies are classified into acquired and genetically determined forms, and excluding HIV-associated lipodystrophy, the other types are extremely uncommon \[[@CR1]\]. No cure for lipodystrophies exists, and treatment targets controlling complications by standard therapeutical approaches, and, in some cases, applying surgical correction of lipohypo- and/or lipohypertrophic affected body areas \[[@CR2]\].

Since 2002 \[[@CR3]\], recombinant human methionyl leptin (metreleptin, Amylin Pharmaceuticals, San Diego, CA, USA) has been employed to treat the metabolic and hepatic complications of rare lipodystrophies, with reasonable results in terms of diabetes control, reduced hypertriglyceridemia, and improvement of hepatic steatosis \[[@CR4]\]. This treatment seems to be effective for long periods \[[@CR5]\] and is well tolerated with few side effects.

Although metreleptin was approved by the Japanese Health Authorities in 2013 and by the US Food and Drug Administration more recently \[[www.fda.gov/newsevents/newsroom/pressannouncements/ucm387060.htm](http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm387060.htm)\] only for rare lipodystrophic syndromes, some limitations \[[@CR6]\] exist in relation to the open-label character of these studies, obviously associated with the infrequent nature of these syndromes. In keeping with the goal of obtaining more evidence of the effectiveness of human recombinant leptin in treating uncommon lipodystrophies, we present our experience of using this hormone for nine patients with different rare lipodystrophic syndromes. The aim of this work was to confirm the efficacy of metreleptin for improving metabolic control, hypertriglyceridemia, and hepatic steatosis in patients with genetic lipodystrophies.

Patients and methods {#Sec2}
====================

The Agencia Española del Medicamento approved the treatment with metreleptin for these patients as compassionate use, and the study was conducted according to the ethical guidelines of the Helsinki Declaration. Patients or their parents gave informed consent for participation in the study and publication of clinical and genetic information.

Patients and study design {#Sec3}
-------------------------

Nine patients with genetic lipodystrophic syndromes were enrolled. All of the patients except one \[with familial partial lipodystrophy (FPLD)\] had generalized lipodystrophy: seven with congenital generalized lipodystrophy (Berardinelli-Seip Syndrome, BS) and one with atypical progeroid syndrome (APS). The genetic, demographic, and clinical baseline features of these patients are shown in Table [1](#Tab1){ref-type="table"}.Table 1Genetic and general features of the lipodystrophic patients before metreleptin treatmentPatient \#OriginLipodystrophy typeGeneMutationsSexAgeDuration of diseaseFat lackDMHBPHyperTG1SpainBerardinelli-SeipBSCL2c. 517dupAM22 years22 yearsGYesYesYes2MoroccoBerardinelli-SeipUnknown^a^UnknownF23 months23 monthsGNoNoYes3SpainBerardinelli-SeipBSCL2c.985C\>T/c.507_511delF37 months37 monthsGNoNoYes4SpainBerardinelli-SeipBSCL2c.385_386delinsGGA/c.517dupAF21 years21 yearsGYesNoYes5SpainBerardinelli-SeipBSCL2c.385_386delinsGGA/c.517dupAM8 years8 yearsGYesNoYes6SpainBerardinelli-SeipBSCL2c.385_386delinsGGA/c.517dupAM8 years8 yearsGNo^b^NoYes7PakistanBerardinelli-SeipAGPAT2c.755_763 del TGAGGACCAF8.8 years8.8 yearsGYesNoYes8SpainAtypical progeroid syndromeLMNAc.29C\>TM8 years2 yearsGYesNoYes9SpainFPLD 2LMNAc.895 A\>GF43 years31 yearsPYesYesYesPatient \#AcanthosisPancreatitisHepatic steatosisCardiomyopathyIntellectual disabilityDiabetic complicationsTreatment1YesNoYesNoMildNephropathyMetformin/pioglitazone (30 mg)/insulin (2.2 UI/kg)\
Fenofibrate/n-3 FFA\
Enalapril/losartan\
Amlodipine2YesNoYesNoNo^c^NAAnimal fat-free diet3YesNoYesHypertrophic cardiomyopathyMild^d^NAAnimal fat-free diet4NoYesYesHypertrophic cardiomyopathy\
Aortic and pulmonary stenosisMildProliferative retinopathy/nephropathy/peripheral arterial disease/polyneuropathyMetformin/pioglitazone/insulin (3.9 IU/kg)/fenofibrate/clopidogrel/pentoxifylline5YesYesYesHypertrophic cardiomyopathy\
Aortic stenosisMildNoneMetformin6YesNoYesHypertrophic cardiomyopathy\
Aortic stenosisMildNAMetformin7YesNoYesHypertrophic cardiomyopathy\
Aortic stenosisNoNoneMetformin/insulin (3.2 UI/kg)8No^e^NoYesDilated cardiomyopathyNoNoneMetformin\
Aspirin/digoxin/furosemide\
Captopril/bisoprolol9YesNoYesNoNoNonePioglitazone/Insulin (1.4 UI/kg)\
Fenofibrate/FFA n-3\
Atorvastatin/ezetimibe\
Valsartan/hydrochlorothiazide/amlodipine*DM* diabetes mellitus, *HyperTG* hypertriglyceridemia, *HBP* high blood pressure, *G* generalized, *P* partial, *NA* not applicable, *FFA* free fatty acid^a^No mutations in AGPAT2, BSCL2, or CAV1 genes^b^Impaired glucose tolerance^c^Hyperactivity^d^Psychomotor delay^e^Leukomelanodermic papulas

The inclusion criteria were the presence of a genetic lipodystrophic syndrome plus diabetes mellitus, defined according to the criteria of the American Diabetes Association \[[@CR7]\], and/or plasma triglycerides higher than 2.26 mmol/L (200 mg/dL) and/or being on triglycerides-lowering drugs. Exclusion criteria were pregnancy, serious liver disease, cancer, or renal failure. Patient ages ranged from 23 months to 44 years, and five patients were male and four female. The study was designed as a retrospective, open-label study at the Complexo Hospitalario Universitario de Santiago de Compostela (Spain). Metreleptin was kindly provided first by Amylin Pharmaceuticals (San Diego, CA, USA) and later by AstraZeneca (London, UK), although all of the data were held by the academic investigators. No placebo-treated control group was included because of the rarity and severity of these syndromes.

Metreleptin was self-administered (or parent-administered) subcutaneously every 12 or 24 h, depending on the supplied volume (every 12 h in those receiving more than 1 mL (5.14 mg/d), patients \#1 and \#9). The replacement dose was calculated based on weight, and the final dose ranged between 0.05 and 0.24 mg/kg/day, with a median of 0.08 mg/kg/day, and was adjusted to achieve metabolic control, taking weight loss into account \[[@CR4], [@CR5]\]. Patients were seen every month for the first 6 months, and every 3 months for the rest of the first year, and then every 6--12 months thereafter. For patients on insulin treatment, the dose was reduced (20 %) every 3 months if the hemoglobin A1c (Hb A1c) value fell below 7 %. Other diabetes medications were stopped or the dose reduced if a patient reached good metabolic control. Lipid-lowering medication was stopped when plasma triglycerides were under 2.26 mmol/L (200 mg/dL). The possible side effects were self- or parent reported in every visit.

Methods {#Sec4}
-------

Height and body weight were measured using a stadiometer and a digital balance. The waist circumference was taken using a flexible tape as the smallest standing horizontal circumference between the ribs and the iliac crest.

Fasting serum samples were analyzed for glucose, triglycerides, high-density lipoprotein-cholesterol (HDL-c), leptin and insulin, as described previously \[[@CR8]\]. Blood Hb A1c was measured using ion-exchange high-performance liquid chromatography (Bio-Rad Laboratories Inc., Hercules, CA, USA). Alanine transaminase (ALT), aspartate transaminase (AST), and gamma-glutamyltransferase were determined by enzymatic methods using an ADVIA analyzer (Siemens, Bayer Diagnostics, Tarrytown, NY, USA). Thyroid-stimulating hormone, free thyroxine, and free triiodothyronine were measured by chemiluminescence using ADVIA Centaur (Bayer Diagnostics, Tarrytown, NY, USA).

Statistical analysis {#Sec5}
--------------------

Data are shown as the mean ± standard deviation. Because of the small number of patients and the non-normal distribution of the variables, non-parametric analysis was carried out using the Wilcoxon signed-rank test. A *p* value of less than 0.05 was taken to indicate statistical significance. All analyses were carried out using the IBM SPSS 22.0 package.

Results {#Sec6}
=======

Anthropometric and auxological data are shown in Table [2](#Tab2){ref-type="table"}. Metreleptin treatment was well tolerated for long periods of time (in some cases more than 5 years) without remarkable side effects. Treatment duration ranged from 9 months to 5 years, 9 months (median: 3 years). Only one patient (\#9) reported transitory nauseas at the beginning of treatment (first week). Patient \#1 voluntarily stopped metreleptin after 2 years because of the appearance of proximal lower limb myopathy, which was not considered related to the drug. The muscular symptoms spontaneously disappeared 6 months later, and metreleptin was resumed after one year because of a serious worsening of metabolic control (Fig. [1](#Fig1){ref-type="fig"}a).Table 2Anthropometric and auxological data for the lipodystrophic patients before and after metreleptin treatmentPatient \#AgeMonths of treatmentMetreleptin dose (mg/kg bw)Height (cm) \[P\]Weight (kg) \[P\]BMI (kg/m^2^) \[P\]Waist circumference (cm)Tanner stageLast visitInitialLast visitBeforeLast visitBeforeLast visitBeforeLast visitBeforeLast visitBeforeLast visit124 years360.080.13171 \[NA\]171 \[NA\]75.4 \[NA\]72.3 \[NA\]25.8 \[NA\]24.7 \[NA\]8380NANA24 years260.0130.05589 \[95\]107 \[95\]12.9 \[50\]14.2 \[25\]16.3 \[50\]12.4 \[\< 3\]5549II34 years, 9 months210.0150.078103 \[\>97\]119 \[\>97\]17.5 \[97\]23 \[97\]16.5 \[55\]16.2 \[75\]5652II425 years630.080.1151 \[NA\]151 \[NA\]41 \[NA\]39 \[NA\]17.9 \[NA\]17.1 \[NA\]6159NANA512 years630.020.06145 \[\>97\]170 \[\>97\]33 \[90\]56 \[92\]15.7 \[25\]19.4 \[60\]8378IIV612 years630.020.05146 \[\>97\]169 \[\>97\]33.4 \[90\]55.6 \[92\]15.8 \[25\]19.5 \[60\]8278IIV710 years, 8 months90.040.08123 \[5\]127 \[\<3\]21.7 \[3\]21.8 \[\<3\]14.3 \[\<3\]13.5 \[\<3\]5850II813 years690.060.08141 \[97\]150 \[25\]27.1 \[55\]29.1 \[\<3\]13.6 \[3\]12.9 \[\<3\]6857IIII944 years120.080.24163 \[NA\]163 \[NA\]85.7 \[NA\]87 \[NA\]32.3 \[NA\]32.7 \[NA\]106108NANA*bw* body weight, *P* percentile, *NA* not applicableFig. 1Time-course of Hb A1c (**a**) and plasma triglycerides (**b**) during metreleptin treatment. \*1 year without metreleptin (patient \#1); ^†^heart transplant (patient \#8)

Special concerns about weight loss or insufficient weight gain have arisen with regard to children (Table [2](#Tab2){ref-type="table"}). Patient \#2 (BS syndrome) had a decreased baseline weight from the 50th percentile to 25th percentile at the last visit (2 years, 2 months of treatment), and patient \#8 (APS) had a decreased baseline weight from 55th percentile to the 3rd percentile (after 5 years, 9 months of treatment). In this last patient, the poor auxological outcomes were probably related to the APS. Patient \#7 had experienced badly controlled diabetes mellitus since age 4 years; in this patient, her low percentiles were probably related to this poor metabolic control.

Biochemical parameters are shown in Table [3](#Tab3){ref-type="table"}. All of the patients were euthyroid. Patients with BS syndrome (\#1 to \#7) were analyzed as a separated group.Table 3Biochemical data for the lipodystrophic patients before and after metreleptin treatmentPatient \#A1c (%)Glucose (mmol/L)TG (mmol/L)HDL-c (mmol/L)Insulin (mIU/L)HOMA-IRLeptin (ng/mL)BeforeLast visitBeforeLast visitBeforeLast visitBeforeLast visitBeforeLast visitBeforeLast visitBeforeLast visit110.47.614.68.73.82.20.80.8NANANANA0.225.524.84.64.94.49.727.80.540.8529.51.56.50.30.511.53ND5.04.054.112.981.640.490.6416324.329.74.50.53.1415.07.521.116.128.2210.40.490.98NANANANA0.111.458.15.411.28.425.83.430.520.6714542.173.215.90.228.965.95.65.95.820.31.930.650.818164.748.116.90.249.7713.66.316.67.56.451.110.540.59NANANANA1.726Mean ± SD9.6 ± 4.16.0 ± 1.2\*11.2 ± 6.67.9 ± 4.115.3 ± 9.63.1 ± 3.3\*0.58 ± 0.10.76 ± 0.1\*130 ± 8433 ± 26\*39 ± 299.4 ± 8\*0.5 ± 0.622 ± 15\*810.67.59.74.432.70.940.650.651908.7831.70.717.999.611.312.710.30.81.90.80.9NANANANA14.498Mean ± SD9.8 ± 3.56.8 ± 2.0\*11.2 ± 5.77.7 ± 3.815.6 ± 11.52.7 ± 3.0\*0.61 ± 0.10.76 ± 0.1\*141 ± 6528 ± 26\*48 ± 337.9 ± 7\*2.1 ± 4.730 ± 29\*Patient \#AST (IU/L)ALT (IU/L)GGT (IU/L)Cr (μmol/L)UA (μmol/L)BeforeLast visitBeforeLast visitBeforeLast visitBeforeLast visitBeforeLast visit1341854462319533531530927533170314327273535724433044915859833427272262564140121102524115ND62ND422510022130588121ND44ND35768313121336816ND44ND44671723362218ND1820208200Mean ± SD108 ± 9624 ± 13\*105 ± 4639 ± 15\*79 ± 7622 ± 11\*31 ± 2038 ± 14277 ± 156319 ± 9381413430228324993527ND20291922192532467153178208Mean ± SD101 ± 8925 ± 12\*122 ± 8636 ± 14\*101 ± 10735 ± 28\*39 ± 2539 ± 13257 ± 146294 ± 95*TG* triglyceride, *NA* not applicable because of insulin treatment, *ND* not determined, *AST* aspartate transaminase, *ALT* alanine aminotransferase/alanine transaminase, *GGT* gamma-glutamyltransferase, *Cr* creatinine, *UA* uric acid, *ND* not determined\* *p* \< 0.05 vs before metreleptin treatment

Regarding metabolic control, all BS patients with diabetes achieved acceptable Hb A1c values during the first year (from 11.8 to 6.7 % on average), except patient \#4. This patient had poor adherence (Fig. [1](#Fig1){ref-type="fig"}a). At the last visit, Hb A1c was 2.97 % points lower on average compared with the starting values in this group of patients. On the other hand, the insulin dose could be reduced in patient \#1 and \#7, from 2.2 and 3.2 IU/kg to 0.6 and 1.89 IU/kg, respectively. Other anti-diabetic medications (metformin and pioglitazone) could be stopped during the treatment, but, except in patient \#6, had to be re-introduced later because of worsening HbA1c values.

Insulin sensitivity improved after metreleptin treatment in all patients with the exception of the patient \#4, as evaluated by basal insulin plasma levels, HOMA-IR index (Table [3](#Tab3){ref-type="table"}), or insulin requirements.

Metreleptin halved plasma triglycerides levels (Fig. [1](#Fig1){ref-type="fig"}b) after 3 months of metreleptin treatment in patients with BS syndrome. At the last visit, plasma triglycerides were reduced by 78 % in this group of patients (Table [3](#Tab3){ref-type="table"}). Except in patient \#4, fenofibrate or n-3 free fatty acids were stopped at the beginning of treatment. Also, HDL-c was significantly increased by 31 % (Table [3](#Tab3){ref-type="table"}).

All of the BS patients had hepatic steatosis as evaluated by ultrasonography, and except patient \#7, they also had nonalcoholic steatohepatitis (NASH) (Table [3](#Tab3){ref-type="table"}). In the first trimester alone, metreleptin reduced both AST and ALT by 30 %; and, at the last visit, this decrease in AST and ALT deepened to 74 and 61 %, respectively (Table [3](#Tab3){ref-type="table"}). As a surrogate endpoint of hepatomegaly, waist circumference was reduced in all patients by an average of 4.6 cm (Table [2](#Tab2){ref-type="table"}; Fig. [2](#Fig2){ref-type="fig"}b). In patients \#2 and \#3, acanthosis nigricans significantly improved (Fig. [2](#Fig2){ref-type="fig"}a) after 1 year of treatment. The metreleptin dose was modified according the main endpoints (Hb A1c, triglycerides and transaminases) and weight loss.Fig. 2Effect of metreleptin on a young girl (age 23 months old, patient \#2) with regard to acanthosis nigricans and hepatic steatosis. *Arrows* show the improvement in the skin lesions (**a**) and the reduction in abdominal circumference (**b**)

The patient with APS (\#8) experienced changes in Hb A1c, triglycerides and, plasma transaminases similar to those observed in BS patients. This patient underwent a heart transplant at age 12 years because of a severe dilated cardiomyopathy. Both metabolic control and triglycerides levels worsened after surgery (Fig. [1](#Fig1){ref-type="fig"}), probably in relation to severe stress and glucocorticoid treatment.

The patient with FPLD (\#9) was the only one in this cohort for whom metreleptin did not improve metabolic control despite a very high dose \[0.24 mg/(kg day)\]. The treatment was stopped after 1 year in agreement with the patient.

Discussion {#Sec7}
==========

In this study, we confirm that metreleptin significantly improved metabolic and hepatic complications in patients with genetic generalized lipodystrophy, and its effects were maintained for long periods of time (more than 5 years in four patients). No relevant side effects were reported, and the weight loss was in the range of other studies \[[@CR9]\].

Metreleptin treatment was not effective, however, in improving metabolic control in the only patient with type 2 FPLD; although the drug allowed cessation of lipid-lowering medication, this patient's triglycerides levels were lower with the standard medication (fenofibrate plus n-3 free fatty acid). A previous group \[[@CR4]\] reported that metreleptin was effective for decreasing Hb A1c in five of six patients with type 2 FPLD over 12 months of treatment and was effective in all of them for decreasing triglycerides. However, the majority of these patients had low baseline leptin concentrations (\<5 ng/mL), while our patient had higher baseline leptin levels (14.4 ng/mL). Because the degree of hypoleptinemia seems to be critical in the effectiveness of metreleptin treatment \[[@CR10]\], Simha et al. \[[@CR11]\] compared the effect of this treatment in two groups of patients with type 2 FPLD, one with severe hypoleptinemia (SH, 1.9 ng/mL on average) and the other with moderate hypoleptinemia (MH, 5.3 ng/mL on average). They concluded that metreleptin replacement therapy was equally effective in FPLD patients with both SH and MH in reducing serum and hepatic triglyceride levels but did not improve hyperglycaemia. In a more extended study of metreleptin treatment, Chan et al. \[[@CR5]\] enrolled 14 people with FPLD, and although the global results on metabolic control, lipid profile, and hepatic steatosis were good, no specific information about patients with FPLD was provided. Taken together, the evidence suggests that severe hypoleptinemia could be a determinant of the magnitude of improvement of metabolic control in patients with FPLD who are treated with metreleptin.

Focusing on BS patients, metreleptin reduced Hb A1c by 2.97 points in agreement with previous reports \[[@CR5]\]. Also, the reduction of triglycerides was remarkable (78 %). Chan et al. \[[@CR5]\] reported a similar reduction (73 %) after three years of treatment. Strikingly, HDL-c levels significantly increased (31 %), whereas other studies found no changes in HDL-c \[[@CR4], [@CR5], [@CR9], [@CR11]\], although a tendency to increase was observed in the US National Institutes of Health study \[[@CR5]\]. We do not have a clear explanation for this discrepancy, but a longer period with low triglycerides levels might be one possibility.

Insulin sensitivity improved in all patients with generalized lipodystrophy except in patient \#4, as measured by HOMA, plasma insulin level reduction, or lower insulin requirement. In those patients without insulin treatment, the basal insulin level reduction ranged from 64 to 95 %. The improvement in insulin sensitivity after metreleptin has been reported by others using different approaches \[[@CR9], [@CR12]--[@CR14]\]. The mechanisms responsible for insulin resistance reduction observed during metreleptin treatment continue to be a matter of controversy and are beyond the current scope; however, the reduction in lipid accumulation in both liver and muscles---along with the resulting lower lipid toxicity probably associated with a lower energy uptake---seems to be a plausible explanation \[[@CR6]\].

The plasma insulin reduction would explain the significant improvement in acanthosis nigricans observed in the two younger children; however, this change did not occur in the older patients despite improved in insulin sensitivity. This result underlines the importance of starting metreleptin replacement as soon as possible.

Hepatic steatosis and NASH are common complications of these rare lipodystrophic syndromes, which in some cases can evolve to cirrhosis. All patients had hepatic steatosis as evaluated by liver ultrasonography, and seven also had NASH. In less than 6 months, we observed a significant reduction in liver enzymes after metreleptin treatment, which was sustained over time, and also a reduction in abdominal circumference (Table [2](#Tab2){ref-type="table"}). Others have also reported improvement in hepatic enzymes, as a surrogate marker of NASH, after metreleptin treatment \[[@CR5], [@CR12], [@CR13], [@CR15]\]. Recently, Safar Zadeh et al. \[[@CR16]\], analyzing hepatic biopsies, demonstrated that leptin replacement reversed hepatic steatosis and NASH to a significant degree. Although they were unable to identify an improvement in fibrosis, their patients showed no progression of this damage. The precise mechanism of leptin action on fatty liver is still poorly understood. Leptin acts at the hypothalamus, reducing appetite, so a decrease in energy uptake would potentially allow for mobilization of stored triglycerides from the liver \[[@CR14], [@CR15]\].

Six of the nine studied patients were children under age 9 years (age range 23 months to 8.8 years of age). In all six, metreleptin was effective in terms of metabolic control, triglyceride reduction, and fatty liver disease improvement, for more than 21 months on metreleptin except patient \#7 (9 months), and more than 5 years in four patients. These results contrast with those reported by Beltrand et al. \[[@CR17]\], who identified partial or total resistance after 28 months of metreleptin replacement in five of eight children with BS syndrome. The authors argued that a possible cause of this resistance was the presence of neutralizing anti-leptin antibodies, measured in two patients. This factor as a cause of reduced effectiveness in lipodystrophic patients on metreleptin has not been reported elsewhere, but has been reported in patients with congenital leptin deficiency under similar treatment \[[@CR18]\]. On the other hand, in the largest studied cohort \[[@CR5]\], with a 53 % pediatric population, no mention was made of an effect reduction of or resistance to metreleptin treatment over at least three years of treatment. All of these data reinforce the need for more extended studies in pediatric populations with generalized lipodystrophy to establish the real effectiveness of this treatment.

To the best of our knowledge, patient \#8 is the first case reported with APS to be treated with metreleptin for more than 5 years. At the age of 8 years, this patient was diagnosed with diabetes mellitus, severe hypertriglyceridemia, NASH, and dilated cardiomyopathy, and started treatment with metreleptin. Metreleptin was successful in controlling the metabolic and hepatic complications; however, his heart disease worsened, and at age of 12, the patient entered the final stages of his cardiac function with a very limited quality of life. Because of his perfect metabolic control and normal transaminase levels, we decided, in agreement with the patient and his parents, to submit the case to our regional pediatric transplant commission and the boy underwent a successful heart transplant in May 2013. After surgery, the patient suffered a worsening of glucose metabolism and lipid profile, probably because of glucocorticoid treatment; however, after increasing metreleptin dose and the addition of metformin, these biochemical parameters improved significantly.

In summary, with this study, we extend the experience with the effectiveness of metreleptin in the treatment of genetic lipodystrophies. This hormone is effective for long periods in people with generalized lipodystrophy associated with severe hypoleptinemia for controlling diabetes, hypertriglyceridemia, and hepatic steatosis, without remarkable side effects.
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